Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO

Figuring it has the backing of the pharma industry writ-large—and doubling down on the social worth of its new Alzheimer's disease drug—Eisai is playing it cool after the Centers for Medicare and Medicaid Services (CMS) rebuffed a petition to overturn coverage constraints on its new launch Leqembi and other anti-amyloid medicines.